<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flecainide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flecainide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flecainide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12474" href="/d/html/12474.html" rel="external">see "Flecainide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13302" href="/d/html/13302.html" rel="external">see "Flecainide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708772"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Flecainide was included in the National Heart Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had an MI more than 6 days but less than 2 years previously. An excessive mortality or nonfatal cardiac arrest rate was seen in patients treated with flecainide compared with that seen in patients assigned to a carefully matched placebo-treated group. This rate was 5.1% for flecainide and 2.3% for the matched placebo. The average duration of treatment with flecainide in this study was 10 months.</p>
<p style="text-indent:-2em;margin-left:2em;">The applicability of the CAST results to other populations (eg, those without recent MI) is uncertain, but at present, it is prudent to consider the risks of Class ΙC agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable in patients without life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ventricular proarrhythmic effects in patients with atrial fibrillation/flutter:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter (PAF). Ventricular tachycardia was experienced in 0.4% of these patients. Of 19 patients in the literature with chronic atrial fibrillation (CAF), 10.5% experienced ventricular tachycardia (VT) or ventricular fibrillation (VF). Flecainide is not recommended for use in patients with CAF. Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased premature ventricular contractions (PVCs), VT, VF, and death.</p>
<p style="text-indent:-2em;margin-left:2em;">As with other Class Ι agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide. Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866905"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Flecainide;</li>
<li>APO-Flecainide;</li>
<li>Auro-Flecainide;</li>
<li>JAMP Flecainide;</li>
<li>MAR-Flecainide;</li>
<li>NRA-Flecainide;</li>
<li>Tambocor</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F171562"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiarrhythmic Agent, Class Ic</li></ul></div>
<div class="block doa drugH1Div" id="F171522"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03c02764-7813-41e6-9184-71c42978fdfe">Fetal tachycardia, sustained</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fetal tachycardia, sustained (maternal/transplacental administration) (off-label use): </b>Oral: 100 to 300 mg/day in divided doses administered every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24763516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24763516'])">Ref</a></span>). Adjust dose to fetal response. Some studies targeted maternal blood levels between 0.2 and 1 mcg/mL. Maximum dose: 450 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29246961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29246961'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41b31b11-f727-42eb-b994-63f75da18ba6">Paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardias (prevention):</b> Oral: Initial: 50 mg every 12 hours; increase by 50 mg twice daily at 4-day intervals; maximum dose: 300 mg/day. The AHA/ACC/HRS atrial fibrillation guidelines recommend a maximum dose of 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias (prevention):</b> Oral: Initial: 50 to 100 mg every 12 hours; increase by 50 mg twice daily at 4-day intervals; maximum: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-10758053','lexi-content-ref-28339995','lexi-content-ref-21616285','lexi-content-ref-23286974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-10758053','lexi-content-ref-28339995','lexi-content-ref-21616285','lexi-content-ref-23286974'])">Ref</a></span>). Some patients inadequately controlled with or intolerant to dosing every 12 hours may require dosing every 8 hours. <b>Note:</b> Initiate therapy in a hospital setting in patients with sustained ventricular tachycardia. Use of higher initial doses and more rapid dosage adjustments have resulted in an increased incidence of proarrhythmic events and congestive heart failure, particularly during the first few days. Do not use a loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d37a5be-edb3-421c-9ad8-48fbd9bd92fd">Ventricular premature beats</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular premature beats (off-label use)</b>
<b>:</b> Oral: 50 to 200 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>). According to the prescribing information, may increase by 50 mg twice daily at 4-day intervals; maximum: 400 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9998ecf1-cec8-46bc-96a5-5289902ef8d0">Atrial fibrillation/flutter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter (pharmacological cardioversion) (off-label dose):</b> Oral: <b>Note:</b> May be used on an outpatient basis (“Pill-in-the-pocket”). An initial inpatient cardioversion trial should have been successful before sending patient home on this approach. Patient must be taking an AV nodal-blocking agent (eg, beta-blocker, nondihydropyridine calcium channel blocker) prior to initiation of antiarrhythmic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-15575054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-15575054'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;70 kg: 200 mg; may not repeat in ≤24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">≥70 kg: 300 mg; may not repeat in ≤24 hours</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from another antiarrhythmic agent:</b> Allow for 2 to 4 half-lives of the other agent after discontinuation to pass before initiating flecainide therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991535"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Flecainide has a narrow therapeutic index, and the half-life is prolonged in patients with kidney impairment. In patients with kidney impairment, monitor serum trough concentrations (especially in patients with CrCl ≤35 mL/minute/1.73 m<sup>2</sup>) and ECG parameters frequently following initiation of therapy or dose adjustments and periodically during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25870032','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25870032','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment is likely to be necessary for pharmacological cardioversion of atrial fibrillation or flutter “pill-in-the-pocket” dosing, as use of this approach should be infrequent enough to avoid accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;35 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Initial: No dosage adjustment necessary; consider obtaining serum trough concentrations to guide dosage adjustments in addition to the anticipated clinical response; dose increases should be made cautiously and at intervals of ~7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤35 mL/minute/1.73 m<sup>2</sup>: Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); subsequent dose adjustments should preferentially be determined based on serum trough concentrations in addition to the anticipated clinical response; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); dose increases should be made no more frequently than every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>): <b>Note:</b> Use with extreme caution. In a retrospective evaluation of 5 dialysis patients receiving chronic flecainide therapy, significant variability (&gt;7-fold) of dose-corrected steady-state plasma concentrations was observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7974623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7974623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); subsequent dose adjustments should preferentially be determined based on serum trough concentrations in addition to the anticipated clinical response; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7974623','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7974623','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); dose increases should be made no more frequently than every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3134365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3134365'])">Ref</a></span>): <b>Note:</b> Use with extreme caution. In a retrospective evaluation of 5 dialysis patients receiving chronic flecainide therapy, extreme variability (&gt;7-fold) of dose-corrected steady-state plasma concentrations was observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7974623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7974623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); subsequent dose adjustments should preferentially be determined based on serum trough concentrations in addition to the anticipated clinical response; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7974623','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7974623','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); dose increases should be made no more frequently than every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Not significantly removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3132493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3132493'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); subsequent dose adjustments should preferentially be determined based on serum trough concentrations in addition to the anticipated clinical response; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); dose increases should be made no more frequently than every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Not likely to be significantly removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); subsequent dose adjustments should preferentially be determined based on serum trough concentrations in addition to the anticipated clinical response; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>); dose increases should be made no more frequently than every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3145942','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988386"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however elimination from the plasma may be slower in patients with hepatic impairment. Use with caution; obtain plasma concentrations to guide dosage adjustments. Dose increases should be made very cautiously at intervals &gt;4 days and serum concentrations monitored frequently.  Frequent plasma level monitoring is required in patients with severe hepatic impairment; if unavailable, use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F171523"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F171545"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13302" href="/d/html/13302.html" rel="external">see "Flecainide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa784e5b-ce8f-4b4a-831c-b89d1be67b93">Arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arrhythmias: </b></p>
<p style="text-indent:-2em;margin-left:4em;">BSA-directed dosing: Use caution with dose titration, as small change in dose may result in disproportionate increase in plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≤6 months: Oral: Initial: 50 mg/m<sup>2</sup>/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m<sup>2</sup>/<b>day</b>; higher doses have been associated with an increased risk of proarrhythmic effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;6 months, Children, and Adolescents: Oral: Initial: 100 mg/m<sup>2</sup>/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m<sup>2</sup>/<b>day</b>; higher doses have been associated with an increased risk of proarrhythmic effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: Limited data available; dosing regimens variable: Infants, Children, and Adolescents: Oral: Initial: 1 to 3 mg/kg/day divided every 8 hours; may titrate dose at 4-day intervals; usual maintenance range: 3 to 6 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1'])">Ref</a></span>); an average effective dose of 4 mg/kg/day was reported in an expert analysis of literature and clinical experience (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1462922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1462922'])">Ref</a></span>); maximum daily dose: 8 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1462922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1462922'])">Ref</a></span>); higher doses have been associated with an increased risk of proarrhythmic effects.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130530"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51110538"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, elimination from the plasma may be slower in patients with hepatic impairment. Use with caution; obtain plasma concentrations to guide dosage adjustments. Dose increases should be made very cautiously at intervals &gt;4 days and serum concentrations monitored frequently. Frequent plasma level monitoring is required in patients with severe hepatic impairment; if unavailable, use is not recommended.</p></div>
<div class="block arsc drugH1Div" id="F56291724"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Proarrhythmic effects/conduction disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially fatal proarrhythmic effects (including <b>ventricular premature contractions</b>, <b>ventricular tachycardia</b>, and <b>ventricular fibrillation</b>) have been reported in patients with atrial fibrillation without structural heart disease who received flecainide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>). Additionally, <b>prolongation of P-R interval on ECG</b>, <b>widened QRS complex on ECG</b>, and <b>prolonged QT interval on ECG</b>, <b>atrioventricular block</b>, or right <b>bundle branch block</b> are possible, leading to <b>sinus bradycardia</b>, <b>sinus pause</b>, <b>sinoatrial arrest</b>, or <b>torsades de pointes</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037','lexi-content-ref-4006779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037','lexi-content-ref-4006779'])">Ref</a></span>). The incidence of proarrhythmic effects with flecainide use is lower in patients without structural heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>); one study noted a &lt;3% incidence of sustained ventricular arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14678922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14678922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; flecainide may unmask the ECG pattern of Brugada syndrome, thereby inducing ventricular tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>). Additionally, flecainide may promote reentry in ventricular tissue via inhibition of rapid sodium channels (slowing phase 0) and inhibition of the slow calcium channel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27957216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27957216'])">Ref</a></span>). Sodium channel blockade also slows conduction through all cardiac conduction pathways, leading to widened QRS, bundle branch block, and prolonged PR interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27957216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27957216'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most patients experience proarrhythmic effects or conduction disturbances within the first 1 to 3 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2513143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2513143'])">Ref</a></span>). Another study reported events within the 12-week period of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28765762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28765762'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Large dose escalations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3107364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3107364'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sick sinus syndrome (or other sinus node dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25717355','lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25717355','lexi-content-ref-32044037'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sustained ventricular tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3107364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3107364'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Atrioventricular conduction abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25717355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25717355'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">1:1 Atrioventricular conduction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When treating atrial fibrillation or atrial flutter, 1:1 atrioventricular (AV) conduction may occur, resulting in a rapid ventricular rate and hemodynamic compromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34086956','lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34086956','lexi-content-ref-32044037'])">Ref</a></span>). The conduction is reversible with cardioversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34086956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34086956'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; the effects of flecainide on rhythm allow for the organization of atrial fibrillation into atrial flutter. Additionally, flecainide slows conduction through sodium channel blockade, resulting in a slower atrial flutter rate, facilitating 1:1 conduction through the AV node (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34086956','lexi-content-ref-20219811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34086956','lexi-content-ref-20219811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; symptoms associated with 1:1 conduction occur within 30 minutes to a few hours after a dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30033133','lexi-content-ref-20219811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30033133','lexi-content-ref-20219811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Physical activity after a dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30033133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30033133'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dual AV conduction pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30033133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30033133'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Absence of AV nodal blocking agent (eg, beta blocker, non-dihydropyridine calcium channel blocker, digoxin) used concurrently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34086956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34086956'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fatal complications associated with structural heart disease (SDH)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Flecainide use in patients with structural heart disease (SHD) (heart failure, myocardial infarction/ischemia) may exacerbate proarrhythmic events (eg, <b>ventricular arrhythmias</b>) and increase the risk of death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1900101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1900101'])">Ref</a></span>). Acute decompensated <b>worsening of heart</b>
<b>failure</b> is possible in patients with chronic heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action. In ischemic tissue, flecainide causes significant rate-dependent slowing of conduction via sodium channel inhibition, leading to heterogeneous conduction and reentry pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>). Flecainide also exhibits significant negative inotropic properties, which can significantly impact patients with poor cardiac function at baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32044037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32044037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. For patients with heart failure with reduced ejection fraction, flecainide significantly increased the risk of decompensation over a 1-year follow-up (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3098817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3098817'])">Ref</a></span>). In the CAPS study, an onset of ~3 months was suggested based on the Kaplan Meier curve for percent free from new or worsening heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2464919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2464919'])">Ref</a></span>). In the CAST trial, patients were followed up to 10 months; cardiac events and death began nearly immediately after initiation of flecainide and continued to occur over the 10-month period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1900101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1900101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1900101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1900101'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1900101','lexi-content-ref-1512329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1900101','lexi-content-ref-1512329'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F171487"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular arrhythmia (new or exacerbated: 7% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbances (16%; including accommodation disturbance, blurred vision, seeing spots)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (1%), cardiac arrhythmia (new or worsened: 1% to 7%), cardiac failure (≤9%), chest pain (5%), edema (4%), flushing (1% to 3%), palpitations (6%), sinoatrial arrest (1% to 3%), sinus bradycardia (≤1%), sinus pause (1% to 3%), syncope (1% to 3%), tachycardia (1% to 3%), worsening of heart failure (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1% to 3%), skin rash (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), anorexia (1% to 3%), constipation (4%), diarrhea (1% to 3%), dyspepsia (1% to 3%), nausea (9%), vomiting (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (1% to 3%), ataxia (1% to 3%), depression (1% to 3%), drowsiness (1% to 3%), fatigue (8%), headache (10%), hypoesthesia (1% to 3%), insomnia (1% to 3%), malaise (1% to 3%), paresis (1% to 3%), paresthesia (1% to 3%), vertigo (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (5%), tremor (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, complete atrioventricular block, hypertension, hypotension, second degree atrioventricular block</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, exfoliative dermatitis, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, flatulence, swelling of lips, swelling of mouth, swollen tongue, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, amnesia, apathy, confusion, depersonalization, euphoria, neuropathy, seizure, speech disturbance, stupor, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation, eye pain, nystagmus disorder, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, pneumonitis, pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Bundle branch block, prolongation of J-T interval on ECG, prolongation P-R interval on ECG (Echt 2020), torsades de pointes (Echt 2020), widened QRS complex on ECG (Echt 2020)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Exacerbation of cardiac arrhythmias (Echt 2020), prolonged QT interval on ECG (Echt 2020), supraventricular cardiac arrhythmias (Echt 2020), ventricular fibrillation (Echt 2020), ventricular premature contractions (Echt 2020), ventricular tachyarrhythmia (Echt 2020), ventricular tachycardia (Echt 2020), wide complex tachycardia (Echt 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum transaminases</p></div>
<div class="block coi drugH1Div" id="F171502"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to flecainide or any component of the formulation; pre-existing second- or third-degree AV block or with right bundle branch block when associated with a left hemiblock (bifascicular block) (except in patients with a functioning artificial pacemaker); cardiogenic shock; concurrent use of ritonavir.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:0em;margin-top:2em;">According to the American College of Cardiology/American Heart Association/European Society of Cardiology, the use of flecainide is considered contraindicated in patients with structural heart disease (ACC/AHA/HRS [Page 2015]; AHA/ACC/HRS [Al-Khatib 2017])</p></div>
<div class="block war drugH1Div" id="F171484"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• AV block: If second- or third-degree AV block, or right bundle branch block associated with a left hemiblock occur, flecainide therapy should be discontinued unless a temporary or implanted ventricular pacemaker is in place to ensure an adequate ventricular rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with significant hepatic impairment; benefit should outweigh risk. Consider careful monitoring during initiation of therapy. Dose titration should occur only after steady state has been achieved (≥4 days after initiation). Frequent plasma level monitoring is required in patients with severe hepatic impairment; if unavailable, use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with significant renal impairment. Frequent plasma level monitoring is required in patients with severe renal impairment; if unavailable, use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Structural or ischemic heart disease: According to the manufacturer, use with extreme caution in patients with structural heart disease as the risk of death and cardiac events may be increased. Avoid use in patients with structural or ischemic heart disease (ACC/AHA/HRS [Page 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Small changes in dose may lead to disproportionate increases in plasma concentrations in pediatric patients. Following initiation of therapy or changes in dose, obtain plasma trough concentrations and ECG once steady state has been achieved (&gt;5 doses after initiation or change); regular monitoring of trough concentrations and ECG is recommended by the manufacturer during the first year of therapy and during major changes in dietary milk intake as milk may interfere with the absorption of flecainide in pediatric patients (Russell 1989; Thompson 2012; manufacturer's labeling); consider dose reductions when milk is removed from the diet (eg, during weaning or bouts of gastroenteritis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pacemakers: Use with caution in patients with permanent pacemakers or temporary pacing wires; can increase endocardial pacing thresholds and suppress ventricular escape rhythms. Do not use in patients with existing poor thresholds or nonprogrammable pacemakers unless suitable pacing rescue is available. The pacing threshold in patients with pacemakers should be determined at baseline, 1 week after initiation and at regular intervals thereafter.</p></div>
<div class="block foc drugH1Div" id="F171494"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg</p></div>
<div class="block geq drugH1Div" id="F171480"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171504"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Flecainide Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.74 - $2.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.73 - $4.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $3.76 - $5.52</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866906"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tambocor: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p></div>
<div class="block adm drugH1Div" id="F53078818"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: When used for the management of fetal tachycardia (maternal/transplacental administration; off-label use), oral doses are administered to the mother.</p></div>
<div class="block admp drugH1Div" id="F52612847"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. May be administered in children without regard to food; however, administration with milk or milk-based formulas may decrease absorption; monitor serum concentrations closely with any changes in milk or milk-based formula consumption; dose adjustments may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2505692','lexi-content-ref-22729333','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2505692','lexi-content-ref-22729333','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F171497"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardias (prevention):</b> Prevention of paroxysmal atrial fibrillation/flutter associated with disabling symptoms and paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms in patients without structural heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations:</i> Due to safety risks, flecainide should be reserved for symptomatic supraventricular tachycardias (SVTs) in patients without structural or ischemic heart disease who are not candidates for, or prefer not to undergo, catheter ablation and in whom other therapies have failed or are contraindicated (ACC/AHA/HRS [Page 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias (prevention):</b> Prevention of documented life-threatening ventricular tachyarrhythmias (eg, sustained ventricular tachycardia) in patients without structural heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations: </i>Flecainide is an appropriate adjunctive therapy in patients with type 3 long QT syndrome or catecholaminergic polymorphic ventricular tachycardia who are already taking a maximally tolerated beta-blocker but still experiencing symptoms (AHA/ACC/HRS [Al-Khatib 2017]; Benhorin 2000; Chorin 2018; Van der Werf 2011; Watanabe 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Use of flecainide is not recommended in patients with less severe ventricular arrhythmias, even if symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom the benefits of treatment outweigh the risks. Flecainide should not be used in patients with permanent atrial fibrillation (not adequately studied) or recent myocardial infarction. No evidence from controlled trials have demonstrated favorable effects of flecainide on survival or the incidence of sudden death.</p></div>
<div class="block off-label drugH1Div" id="F25725158"><span class="drugH1">Use: Off-Label: Adult</span><p>Atrial fibrillation or flutter (pharmacologic cardioversion); Fetal tachycardia, sustained; Ventricular premature beats</p></div>
<div class="block mst drugH1Div" id="F171570"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flecainide may be confused with fluconazole </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tambocor [DSC] may be confused with Pamelor, Temodar, tamoxifen, Tamiflu</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F171556"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F171489"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May decrease the excretion of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide. Management: Decrease flecainide dose by 50%.   Monitor for QTc interval prolongation and ventricular arrhythmias, and consider monitoring for elevated flecainide concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Flecainide. Management: Canadian labeling recommends avoiding this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May decrease the excretion of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Flecainide may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of PAZOPanib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pindolol: Flecainide may enhance the bradycardic effect of Pindolol. The negative inotropic effects of Pindolol may also be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Flecainide. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of other QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): May enhance the QTc-prolonging effect of QT-prolonging CYP2D6 Substrates. Quinidine (Non-Therapeutic) may increase the serum concentration of QT-prolonging CYP2D6 Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: May enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Bicarbonate (Systemic): May decrease the excretion of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May enhance the adverse/toxic effect of Flecainide. In particular, this combination may significantly impair myocardial contractility and AV nodal conduction.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F171514"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Clearance may be decreased in patients following strict vegetarian diets due to urinary pH ≥8. Milk may interfere with the absorption of flecainide (Russell 1989; Thompson 2012). Management: Dose reduction should be considered when milk is removed from the diet (eg, during weaning or bouts of gastroenteritis). Plasma trough flecainide levels should be monitored during major changes in dietary milk intake.</p></div>
<div class="block pri drugH1Div" id="F13386419"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Flecainide crosses the placenta (Palmer 1990). Placental transfer is not decreased when fetal hydrops is present. Neonatal conduction abnormalities have been reported (AHA [Donofrio 2014]).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated maternal arrhythmias may cause adverse events in the mother and fetus. Flecainide may be used for the ongoing management of pregnant women with highly symptomatic supraventricular tachycardia (SVT). The lowest effective dose is recommended; avoid use during the first trimester if possible (ACC/AHA/HRS [Page 2015]). Use is also recommended for the prevention of SVT in patients with Wolff-Parkinson-White (WPW) syndrome. Until more information is available, when prevention of SVT in patients without WPW syndrome, atrial tachycardia, or atrial fibrillation is needed in pregnancy, flecainide is generally reserved for use when other agents are not effective (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Flecainide (administered maternally) may be considered for the in utero management of fetal SVT or atrial flutter with hydrops or ventricular dysfunction. Flecainide may also be considered for SVT without hydrops or ventricular dysfunction if heart rate is ≥200 bpm, or other rare tachycardias with an average heart rate of ≥200 bpm. In addition, flecainide may be considered for fetal ventricular tachycardia (VT) with normal QTc with or without hydrops but is contraindicated for the treatment of fetal VT when long QT syndrome is suspected or confirmed (AHA [Donofrio 2014]).</p></div>
<div class="block brc drugH1Div" id="F13386420"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Flecainide is present in breast milk (McQuinn 1990; Wagner 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of flecainide is 8% when calculated using the highest average breast milk concentration located and compared to a weight-adjusted maternal dose of 200 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of flecainide was calculated using a milk concentration of 1,529 ng/mL, providing an estimated daily infant dose via breast milk of 0.23 mg/kg/day. This milk concentration was obtained following maternal administration of oral flecainide 100 mg twice daily for 5 days to 11 lactating females, beginning the first day postpartum. The average daily flecainide concentrations in breast milk, and the maternal plasma trough concentrations were variable between subjects; however, the milk/plasma ratio was consistent across the group. Concentrations of flecainide in breast milk were as high as 4 times those in the maternal serum. Based on data from this study, milk concentrations would decline at approximately the same rate as maternal serum concentrations once the medication is discontinued (McQuinn 1990).</p></div>
<div class="block mop drugH1Div" id="F171492"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG, BP, heart rate, periodic serum trough concentrations, especially in patients with renal or hepatic impairment, concomitant administration of amiodarone and pediatric patients.</p></div>
<div class="block rer drugH1Div" id="F171495"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic: Trough concentration: 0.2 to 1 mcg/mL. <b>Note:</b> Pediatric patients may respond at the lower end of the recommended therapeutic range (0.2 to 0.5 mcg/mL) but up to 0.8 mcg/mL may be required.</p></div>
<div class="block pha drugH1Div" id="F171483"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Class Ic antiarrhythmic; slows conduction in cardiac tissue by altering transport of ions across cell membranes; causes slight prolongation of refractory periods; decreases the rate of rise of the action potential without affecting its duration; increases electrical stimulation threshold of ventricle, His-Purkinje system; possesses local anesthetic and moderate negative inotropic effects</p></div>
<div class="block phk drugH1Div" id="F171501"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Nearly complete; may be decreased when administered with milk in pediatric patients (Thompson 2012; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Newborns: Up to ≤29 hours; 3 months: 11 to 12 hours; 12 months: 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: ~8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 12 to 15 years: ~11 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~20 hours (range: 12 to 27 hours); increased in patients with heart failure (NYHA Class III) or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~3 hours (range: 1 to 6 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (30% [range: 10% to 50%] as unchanged drug); feces (5%).</p></div>
<div class="block phksp drugH1Div" id="F57227676"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with end-stage kidney disease, renal clearance is very low as compared to patients with moderate kidney impairment, and the plasma half-life may extend up to 58 hours (Conard 1984).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171505"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-flecainide | Tambocor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Diondel | Flenomid xr | Tambocor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aristocor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Flecainide sandoz | Flecatab | Tambocor</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Apocard retard | Docflecai | Flecainide eg | Flecainide merck-generics | Flecainide retard eg | Flecainide sandoz | Flecateva | Flecateva retard | Tambocor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amarhyton | Felkarid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Flecadura | Flecagamma | Flecainid 1A Pharma | Flecainid aaa | Flecainid AWD | Flecainid Hexal | Flecainid isis | Flecainid micro labs | Flecainid puren | Flecainid ratiopharm | Flecainid sandoz | Flecainid tillomed | Flecainidacetat actavis | Flecainidacetat AL | Flecainidacetat aurobindo | Tambocor</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Flecainid alpharma</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flecainid ratiopharm | Flecainidacetat puren | Tambocor</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Flecainida apotex | Flecainida aurovitas | Flecainida normon | Flecainida qualigen | Flecard</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flecainid alpharma | Flecainide orion | Tambocor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Flecaine | Flecainide Arrow | Flecainide Biogaran | Flecainide Dci | Flecainide eg | Flecainide Qualimed | Flecainide rpg | Flecainide sandoz | Flecainide teva | Flecainide zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Flecainide | Flecainide cox | Flecainide kent | Tambocor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Flecardia | Flecarythm | Tambocor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-flecainide | Tambocor | Vick Flecainide</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Flecainide | Tambocor</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Almarytm | Flecainide | Flecainide aurobindo | Flecainide Doc generici | Flecainide eg | Flecainide Ratiopharm | Flecainide sandoz | Fleiderina | Frequil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Flecainide acetate ko | Flecainide acetate pfizer | Tambocor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fulcard | Tambocor</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Flecain | Flecainide | Flecainide biogaran l.p. | Tambocor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Flecadura | Flecainid aaa | Flecainid isis | Flecainid puren | Flecainideacetaat aurobindo | Tambocor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Flecainide eg | Flecainide sandoz | Tambocor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Flecagamma | Flecainid isis | Flecainid rth | Flecainid sandoz | Tambocor</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Flecainide | Tambocor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Flecainide | Flecainide-acetaat | Flecainide-Acetaat Actavis | Flecainide-Acetaat Sandoz | Tambocor</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Flecainid sandoz | Tambocor | Tambocor retard</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Flecainide bnm | Flecainide Controlled Release | Tambocor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Flecainide | Tambocor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Aristocor | Flecadura | Flecaine lp | Flecainid Hexal | Flecainide acetate holsten | Flecainide Biogaran | Flecainide mylan | Tambocor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Apocard | Tambocor</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Apocard</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amarhyton | Tambocor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-flecainide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Flecainide alternova | Flekainid sandoz | Flekainid stada | Tambocor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Felkarid | Tambocor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Flekainid sandoz | Tambocor</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Flecaine | Flecav</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flekainid sandoz | Lixarit</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Diondel | Tambocor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tambocor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. Published online October 30, 2017. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15575054">
<a name="15575054"></a>Alboni P, Botto GL, Baldi N, et al. Outpatient Treatment of Recent-Onset Atrial Fibrillation With the "Pill-in-the-Pocket" Approach. <i>N Engl J Med</i>. 2004;351(23):2384-2391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/15575054/pubmed" id="15575054" target="_blank">15575054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29246961">
<a name="29246961"></a>Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. <i>J Am Heart Assoc</i>. 2017;6(12):e007164. doi:10.1161/JAHA.117.007164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/29246961/pubmed" id="29246961" target="_blank">29246961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2513143">
<a name="2513143"></a>Anderson JL, Gilbert EM, Alpert BL, et al; Flecainide Supraventricular Tachycardia Study Group. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. <i>Circulation</i>. 1989;80(6):1557-1570. doi:10.1161/01.cir.80.6.1557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2513143/pubmed" id="2513143" target="_blank">2513143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25717355">
<a name="25717355"></a>Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. <i>World J Cardiol</i>. 2015;7(2):76-85. doi:10.4330/wjc.v7.i2.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/25717355/pubmed" id="25717355" target="_blank">25717355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3134365">
<a name="3134365"></a>Bailie GR, Waldek S. Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis. <i>J Clin Pharm Ther</i>. 1988;13(2):121-124. doi:10.1111/j.1365-2710.1988.tb00167.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3134365/pubmed" id="3134365" target="_blank">3134365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27957216">
<a name="27957216"></a>Barman M. Proarrhythmic effects of antiarrhythmic drugs: case study of flecainide induced ventricular arrhythmias during treatment of atrial fibrillation. <i>J Atr Fibrillation</i>. 2015;8(4):1091. doi:10.4022/jafib.1091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/27957216/pubmed" id="27957216" target="_blank">27957216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10758053">
<a name="10758053"></a>Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? <i>Circulation.</i> 2000;11;101(14):1698-1706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/10758053/pubmed" id="10758053" target="_blank">10758053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14557344">
<a name="14557344"></a>Blomstrom-Lundqvist C, Scheinman MM, Aliot EM; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). <i>Circulation.</i> 2003;108(15):1871-1909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/14557344/pubmed" id="14557344" target="_blank">14557344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3132493">
<a name="3132493"></a>Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chiolero R. Hemofiltration clearance of flecainide in a patient with acute renal failure. <i>Intensive Care Med</i>. 1988;14(3):236-237. doi:10.1007/BF00717997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3132493/pubmed" id="3132493" target="_blank">3132493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28339995">
<a name="28339995"></a>Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. <i>Europace.</i> 2018;20(2):370-376. doi:10.1093/europace/euw439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/28339995/pubmed" id="28339995" target="_blank">28339995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34086956">
<a name="34086956"></a>Colangelo T, Johnson D, Ho R. Flecainide-induced atrial flutter with 1:1 conduction complicated by ventricular fibrillation after electrical cardioversion. <i>Tex Heart Inst J</i>. 2021;48(2):e197099. doi:10.14503/THIJ-19-7099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/34086956/pubmed" id="34086956" target="_blank">34086956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30033133">
<a name="30033133"></a>Comelli I, Pigna F, Cervellin G. 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. <i>Am J Emerg Med</i>. 2018;36(11):2131.e3-2131.e5. doi:10.1016/j.ajem.2018.07.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/30033133/pubmed" id="30033133" target="_blank">30033133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6364769">
<a name="6364769"></a>Conard GJ, Ober RE. Metabolism of flecainide. <i>Am J Cardiol</i>. 1984;53(5):41B-51B.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/6364769/pubmed" id="6364769" target="_blank">6364769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3098817">
<a name="3098817"></a>de Paola AA, Horowitz LN, Morganroth J, et al. Influence of left ventricular dysfunction on flecainide therapy. <i>J Am Coll Cardiol</i>. 1987;9(1):163-168. doi:10.1016/s0735-1097(87)80096-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3098817/pubmed" id="3098817" target="_blank">3098817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24763516">
<a name="24763516"></a>Donofrio MT, Moon-Grady AJ, Hornberger LK, et al; American Heart Association Adults with Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2014;129(21):2183-2242. doi:10.1161/01.cir.0000437597.44550.5d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/24763516/pubmed" id="24763516" target="_blank">24763516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1900101">
<a name="1900101"></a>Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. <i>N Engl J Med</i>. 1991;324(12):781-788. doi:10.1056/NEJM199103213241201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/1900101/pubmed" id="1900101" target="_blank">1900101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32044037">
<a name="32044037"></a>Echt DS, Ruskin JN. Use of flecainide for the treatment of atrial fibrillation. <i>Am J Cardiol</i>. 2020;125(7):1123-1133. doi:10.1016/j.amjcard.2019.12.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/32044037/pubmed" id="32044037" target="_blank">32044037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28114840">
<a name="28114840"></a>Ekiz A, Kaya B, Bornaun H, et al. Flecainide as first-line treatment for fetal supraventricular tachycardia. <i>J Matern Fetal Neonatal Med</i>. 2018;31(4):407-412. doi:10.1080/14767058.2017.1286317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/28114840/pubmed" id="28114840" target="_blank">28114840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873418">
<a name="21873418"></a>European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197. doi:10.1093/eurheartj/ehr218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/21873418/pubmed" id="21873418" target="_blank">21873418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7974623">
<a name="7974623"></a>Evers J, Eichelbaum M, Kroemer HK. Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death? <i>Ther Drug Monit</i>. 1994;16(4):349-351. doi:10.1097/00007691-199408000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/7974623/pubmed" id="7974623" target="_blank">7974623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7897134">
<a name="7897134"></a>Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and Amiodarone: Combined Therapy for Refractory Tachyarrhythmias in Infants. <i>J Am Coll Cardiol</i>. 1995;25(5):1195-1198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/7897134/pubmed" id="7897134" target="_blank">7897134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19300276">
<a name="19300276"></a>Ferlini M, Colli AM, Bonanomi C, et al. Flecainide as First-Line Treatment for Supraventricular Tachycardia in Newborns.<i> J Cardiovasc Med (Hagerstown)</i>. 2009;10(5):372-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/19300276/pubmed" id="19300276" target="_blank">19300276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1512329">
<a name="1512329"></a>Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. <i>J Am Coll Cardiol</i>. 1992;20(3):527-532. doi:10.1016/0735-1097(92)90003-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/1512329/pubmed" id="1512329" target="_blank">1512329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Flecainide acetate [prescribing information]. Laurelton, NY: Epic Pharma LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3145942">
<a name="3145942"></a>Forland SC, Cutler RE, McQuinn RL, et al. Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. <i>J Clin Pharmacol</i>. 1988;28(8):727-735. doi:10.1002/j.1552-4604.1988.tb03207.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3145942/pubmed" id="3145942" target="_blank">3145942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2464919">
<a name="2464919"></a>Greene HL, Richardson DW, Hallstrom AP, et al. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). <i>Am J Cardiol</i>. 1989;63(7):393-398. doi:10.1016/0002-9149(89)90306-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2464919/pubmed" id="2464919" target="_blank">2464919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28833310">
<a name="28833310"></a>Hill GD, Kovach JR, Saudek DE, Singh AK, Wehrheim K, Frommelt MA. Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. <i>Prenat Diagn</i>. 2017;37(11):1076-1083. doi:10.1002/pd.5144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/28833310/pubmed" id="28833310" target="_blank">28833310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21931080">
<a name="21931080"></a>Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. <i>Circulation</i>. 2011;124(16):1747-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/21931080/pubmed" id="21931080" target="_blank">21931080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. Published online March 28, 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H,t al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019. pii: S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.2018">
<a name="Manolis.2018"></a>Manolis AS. Ventricular premature beats. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 26, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14678922">
<a name="14678922"></a>McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. <i>Ann Intern Med</i>. 2003;139(12):1018-1033. doi:10.7326/0003-4819-139-12-200312160-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/14678922/pubmed" id="14678922" target="_blank">14678922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2119270">
<a name="2119270"></a>McQuinn RL, Pisani A, Wafa S, et al. Flecainide excretion in human breast milk. <i>Clin Pharmacol Ther</i>. 1990;48(3):262-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2119270/pubmed" id="2119270" target="_blank">2119270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3107364">
<a name="3107364"></a>Morganroth J. Risk factors for the development of proarrhythmic events. <i>Am J Cardiol</i>. 1987;59(11):32E-37E. doi:10.1016/0002-9149(87)90199-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3107364/pubmed" id="3107364" target="_blank">3107364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1615792">
<a name="1615792"></a>Musto B, Cavallaro C, Musto A, et al. Flecainide Single Oral Dose for Management of Paroxysmal Supraventricular Tachycardia in Children and Young Adults. <i>Am Heart J</i>. 1992;124(1):110-115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/1615792/pubmed" id="1615792" target="_blank">1615792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4006779">
<a name="4006779"></a>Nathan AW, Hellestrand KJ, Bexton RS, Spurrell RA, Camm AJ. The proarrhythmic effects of flecainide. <i>Drugs</i>. 1985;29(suppl 4):45-53. doi:10.2165/00003495-198500294-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/4006779/pubmed" id="4006779" target="_blank">4006779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norvir.1">
<a name="Norvir.1"></a>Norvir (ritonavir) [prescribing information]. Chicago, IL: AbbVie Inc; March 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7560629">
<a name="7560629"></a>O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or Flecainide for Prophylaxis of Supraventricular Tachycardia in Infants? <i>J Am Coll Cardiol</i>. 1995;26(4):991-994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/7560629/pubmed" id="7560629" target="_blank">7560629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi:10.1016/j.jacc.2015.08.856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2105628">
<a name="2105628"></a>Palmer CM, Norris MC. Placental transfer of flecainide. <i>Am J Dis Child</i>. 1990;144(2):144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2105628/pubmed" id="2105628" target="_blank">2105628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park MK, ed. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Elsevier/Mosby; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1462922">
<a name="1462922"></a>Perry JC and Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing<i>. </i>
<i>Am Heart J. </i>1992;124(6):1614-1621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/1462922/pubmed" id="1462922" target="_blank">1462922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2500470">
<a name="2500470"></a>Perry JC, McQuinn RL, Smith RT Jr, et al. Flecainide Acetate for Resistant Arrhythmias in the Young: Efficacy and Pharmacokinetics. <i>J Am Coll Cardiol</i>. 1989;14(1):185-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2500470/pubmed" id="2500470" target="_blank">2500470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11823091">
<a name="11823091"></a>Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children &lt;1 year of age. <i>J Am Coll Cardiol</i>. 2002;39(3):517-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/11823091/pubmed" id="11823091" target="_blank">11823091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3147891">
<a name="3147891"></a>Priestley KA, Ladusans EJ, Rosenthal E, et al. Experience With Flecainide for the Treatment of Cardiac Arrhythmias in Children. <i>Eur Heart J</i>. 1988;9(12):1284-1290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3147891/pubmed" id="3147891" target="_blank">3147891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2473403">
<a name="2473403"></a>Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. <i>N Engl J Med</i>. 1989;321(6):406-412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2473403/pubmed" id="2473403" target="_blank">2473403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2505692">
<a name="2505692"></a>Russell GA, Martin RP. Flecainide toxicity. <i>Arch Dis Child</i>. 1989;64(6):860-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/2505692/pubmed" id="2505692" target="_blank">2505692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28765762">
<a name="28765762"></a>Shiga T, Yoshioka K, Watanabe E, et al. Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: a crossover study of flecainide and pilsicainide. <i>J Arrhythm</i>. 2017;33(4):310-317. doi:10.1016/j.joa.2017.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/28765762/pubmed" id="28765762" target="_blank">28765762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22433576">
<a name="22433576"></a>Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. <i>Can J Cardiol</i>. 2012;28(2):125-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/22433576/pubmed" id="22433576" target="_blank">22433576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27554948">
<a name="27554948"></a>Sridharan S, Sullivan I, Tomek V, et al. Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. <i>Heart Rhythm</i>. 2016;13(9):1913-1919. doi:10.1016/j.hrthm.2016.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/27554948/pubmed" id="27554948" target="_blank">27554948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26829115">
<a name="26829115"></a>Strizek B, Berg C, Gottschalk I, Herberg U, Geipel A, Gembruch U. High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia. <i>Heart Rhythm</i>. 2016;13(6):1283-1288. doi:10.1016/j.hrthm.2016.01.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/26829115/pubmed" id="26829115" target="_blank">26829115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25870032">
<a name="25870032"></a>Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. <i>Eur J Clin Pharmacol</i>. 2015;71(5):549-567. doi:10.1007/s00228-015-1832-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/25870032/pubmed" id="25870032" target="_blank">25870032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20219811">
<a name="20219811"></a>Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. <i>BMJ</i>. 2010;340:b4684. doi:10.1136/bmj.b4684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/20219811/pubmed" id="20219811" target="_blank">20219811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22729333">
<a name="22729333"></a>Thompson B, Mangat J, Barton C, Hawcutt DB. Decreased milk drinking causing flecainide toxicity in an older child. <i>BMJ Case Rep</i>. 2012:bcr0220125810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/22729333/pubmed" id="22729333" target="_blank">22729333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21616285">
<a name="21616285"></a>Van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. <i>J Am Coll Cardiol.</i> 2011;57(22):2244-2254. doi:10.1016/j.jacc.2011.01.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/21616285/pubmed" id="21616285" target="_blank">21616285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17407483">
<a name="17407483"></a>Vento M, Tudela BF, Escrig R, Sáenz P, Sánchez A, Cano A. Haemolysis alters plasma flecainide levels in newborn infants. <i>Acta Paediatr</i>. 2007;96(3):466-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/17407483/pubmed" id="17407483" target="_blank">17407483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25068572">
<a name="25068572"></a>Vigneswaran TV, Callaghan N, Andrews RE, et al. Correlation of maternal flecainide concentrations and therapeutic effect in fetal supraventricular tachycardia. <i>Heart Rhythm</i>. 2014;11(11):2047-2053. doi:10.1016/j.hrthm.2014.07.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/25068572/pubmed" id="25068572" target="_blank">25068572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1689933">
<a name="1689933"></a>Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. <i>Am Heart J</i>. 1990;119(3 Pt 1):700-702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/1689933/pubmed" id="1689933" target="_blank">1689933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23286974">
<a name="23286974"></a>Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm. </i>2013;10(4):542-547<i>.</i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/23286974/pubmed" id="23286974" target="_blank">23286974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3138905">
<a name="3138905"></a>Zeigler V, Gillette PC, Ross BA, et al. Flecainide for Supraventricular and Ventricular Arrhythmias in Children and Young Adults. <i>Am J Cardiol</i>. 1988;62(10, pt 1):818-820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flecainide-drug-information/abstract-text/3138905/pubmed" id="3138905" target="_blank">3138905</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8449 Version 329.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
